ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
Michael Brines(Northwell Health), Albert Dahan(Centre for Human Drug Research), Rayaz A. Malik(Manchester Academic Health Science Centre), Rita I. Kirk(Araim Pharmaceuticals (United States)), Monique van Velzen(Leiden University Medical Center), Paolo Proto(Leiden University Medical Center), Ioannis N. Petropoulos(Manchester Academic Health Science Centre), Ann Dunne(Araim Pharmaceuticals (United States)), Claes‐Göran Östenson(Karolinska Institutet), Saad Javed(Manchester Academic Health Science Centre), Anthony Cerami(Araim Pharmaceuticals (United States))
Cited by 143
Related Papers
Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE)
|The Lancet Oncology|2013|1.6k
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project
|The Lancet|2013|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k